Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting antiarrhythmic performance.

C M Pratt1

  • 1Baylor College of Medicine, Coronary Intensive Care Unit, The Methodist Hospital, Houston, Texas 77030, USA. cpratt@bcm.tmc.edu

Journal of Cardiovascular Electrophysiology
|March 25, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative opacification of acrylic intraocular lenses in storage.

Journal of materials science. Materials in medicine·2007
Same author

All that glitters is not gold.

European heart journal·2003
Same author

Analysis of the cilostazol safety database.

The American journal of cardiology·2001
Same author

Central clinical research issues in electrophysiology: report of the NASPE Committee.

Pacing and clinical electrophysiology : PACE·2001
Same author

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.

Circulation·2001
Same author

Factors influencing clinical outcomes after revascularization in the asymptomatic cardiac ischemia pilot (ACIP). ACIP Study Group.

Journal of cardiac surgery·2000
Same journal

Pulsed Field Ablation Is Associated With Fewer Post-Procedural Pericardial Inflammatory Symptoms Compared With Radiofrequency Ablation.

Journal of cardiovascular electrophysiology·2026
Same journal

Single-Cell Transcriptomics and Mendelian Randomization Analysis Reveal Key Genes in Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same journal

Relationship Between Nonuniform Isochrone-Area in Late Activation Mapping and Arrhythmogenic Substrates Related to Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same journal

Clinical Utility of Tissue Proximity Indication With a Variable-Loop Circular Catheter for Pulmonary Vein Isolation.

Journal of cardiovascular electrophysiology·2026
Same journal

Impact of Carina Width on Re-Ablation Rate of Atrial Fibrillation After Primary Cryoballoon-Ablation.

Journal of cardiovascular electrophysiology·2026
Same journal

Mediastinal Air Entrapment During Extravascular ICD Implantation: A Preventable Cause of Elevated Shock Impedance.

Journal of cardiovascular electrophysiology·2026
See all related articles

Clinical trials are essential for antiarrhythmic therapy, moving beyond older observational studies. Understanding trial design and patient factors is crucial for effective treatment of atrial and ventricular arrhythmias.

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Evidence-Based Medicine

Background:

  • Historically, antiarrhythmic therapy relied on observational studies.
  • Current best practices necessitate evidence from large-scale clinical trials.
  • The use of surrogate markers in antiarrhythmic trials has been questioned due to study outcomes like CAST and ESVEM.

Purpose of the Study:

  • To review major clinical antiarrhythmic drug trials from the past decade.
  • To emphasize patient variables and study design issues impacting trial interpretation.
  • To aid clinicians in applying trial results to patient care for arrhythmias.

Main Methods:

  • Review of major clinical antiarrhythmic drug trials published within the last 10 years.
  • Focus on analyzing study design and patient populations.

Related Experiment Videos

  • Emphasis on factors influencing trial outcomes.

    • Main Results:

    • Large clinical trials are now the standard for antiarrhythmic therapy guidance.
    • Surrogate markers have limitations, as demonstrated by specific trials.
    • Patient characteristics (e.g., structural heart disease) significantly affect treatment outcomes.

    Conclusions:

    • Clinicians must critically evaluate study design and patient populations when interpreting antiarrhythmic trial data.
    • Mortality trials are essential for guiding treatment of atrial and ventricular arrhythmias.
    • Understanding these variables is key for applying evidence to individual patient care.